MetaCap

AEON Biopharma (AEON) vs Chemomab Therapeutics (CMMB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Chemomab Therapeutics (CMMB) has outperformed AEON Biopharma (AEON) over the past year, losing 53.0% versus a loss of 85.2%. AEON Biopharma is the larger company by market cap ($10.3 million vs $9.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AEON-85.18%CMMB-52.96%
+71%-11%-94%
Nov 21, 20251 yearNov 20, 2026
AEON-99.98%CMMB-86.84%
+64%-22%-108%
Jan 2, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AEON versus CMMB key metrics
MetricAEONCMMB
Share price$0.123$1.19
Market cap$10.35M$9.58M
1-day change-7.59%+4.39%
YTD return-88.82%-27.88%
1-year return-85.18%-52.96%
5-year return—-96.65%
EPS (TTM)$-3.89$-1.04
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-39.22M$-8.99M
52-week high$1.45$2.99
52-week low$0.106$0.92
Distance from 52-week high-91.52%-60.20%
Analyst consensusstrong_buynone
Avg. price target upside+1379.67%+320.17%
Average volume7.44M102.39K
Shares outstanding84.12M8.05M
Employees8—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CMMB has outperformed AEON by 32.2 percentage points over the past year.

About AEON Biopharma

AEON stock →

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

About Chemomab Therapeutics

CMMB stock →

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis.

Health Care · Biotechnology: Pharmaceutical Preparations

AEON vs CMMB FAQ

Which is bigger, AEON Biopharma or Chemomab Therapeutics?

AEON Biopharma (AEON) is larger, with a market capitalization of $10.35M compared with $9.58M for Chemomab Therapeutics (CMMB).

Which stock has performed better over the past year, AEON or CMMB?

CMMB returned -52.96% over the past 12 months, compared with -85.18% for AEON (price return, excluding dividends). Past performance does not predict future results.

Are AEON Biopharma and Chemomab Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons